Cetus Corporation

Cetus Corporation was one of the earliest dedicated biotechnology companies. Founded in Berkeley, California, in 1971 by Ronald E. Cape, Peter Farley, and Nobel Prize-winning physicist Donald A. Glaser, the company initially pursued industrial biotechnology: it sought automated ways to identify and select microorganisms capable of producing larger quantities of chemical feedstocks, antibiotics, and vaccine components. Its principal operating base later developed in nearby Emeryville, which became closely associated with the company's research and manufacturing activities. During the late 1970s, biotechnology was being reshaped by recombinant DNA, monoclonal-antibody, and gene-expression methods. Cetus shifted toward these emerging molecular-biology platforms and became an important participant in the transition from laboratory genetic engineering to commercial biopharmaceutical development. In 1981 it completed an initial public offering that raised $108 million, described in contemporary accounts as the largest IPO of its kind at that time. The new capital supported a broad and expensive portfolio of therapeutic, diagnostic, and basic-technology programs. One of Cetus's early therapeutic efforts involved beta-interferon, developed with Triton Biosciences through the cloning, expression, modification, and production of the protein. The treatment did not fulfill its initial promise as a broad cancer therapy, although beta-interferon was eventually approved for treating symptoms associated with multiple sclerosis and later marketed as Betaseron. Cetus also made recombinant interleukin-2, or IL-2, its central pharmaceutical program. The company created a proprietary recombinant form by 1983 and worked with Steven Rosenberg on clinical trials. The treatment showed activity against renal cancer, but its substantial adverse effects complicated development. The U.S. Food and Drug Administration declined to approve it in 1990 pending additional information; approval came in 1992 after Cetus had been acquired, and the product became known as Proleukin. Cetus's most enduring technological contribution came from its work in DNA diagnostics and amplification. Through relationships with Perkin-Elmer and Kodak, the company explored instruments and commercial diagnostic kits. In this research environment, chemist Kary Mullis conceived the polymerase chain reaction, or PCR, a method that allows specific DNA sequences to be repeatedly amplified. PCR subsequently became foundational in molecular biology, medical diagnostics, forensic analysis, and genetic research. Mullis received the 1993 Nobel Prize in Chemistry for the discovery, the only Nobel Prize associated with research conducted at a biotechnology company according to the cited reference material. The cost of developing IL-2, combined with the delay in regulatory approval, placed severe pressure on Cetus's finances. The company continued to incur losses, and its chief executive resigned six weeks after the 1990 regulatory setback. Cetus also sold patent rights associated with PCR to Hoffmann-La Roche. In 1991, Cetus was acquired by Chiron Corporation. Chiron continued development of IL-2, which received FDA approval in 1992, and assembled rights related to beta-interferon, which was approved for clinical use in 1993. Cetus therefore ceased to exist as an independent company, but its scientific legacy continued through PCR and through therapeutic products developed from its recombinant-DNA programs.

Cetus Corporation was established in Berkeley, California, in 1971 by Ronald E. Cape, Peter Farley, and Donald A. Glaser. Its original work focused on industrial microorganisms. The company attempted to automate the selection of microbial strains that could produce higher yields of chemical feedstocks, antibiotics, or components used in vaccines. This orientation reflected an early biotechnology model in which biological systems were treated as production platforms for industrial and medical materials. By the end of the 1970s, recombinant DNA, monoclonal antibodies, and gene-expression techniques were creating a new commercial field. Cetus redirected much of its effort toward molecular biology and biopharmaceuticals. Its 1981 public offering raised $108 million, giving the company unusually substantial resources for research and clinical development. Cetus subsequently built programs spanning therapeutic proteins, cancer treatment, diagnostics, and DNA analysis. Although its main establishment was in Berkeley, most operations were conducted in nearby Emeryville. Cetus worked with Triton Biosciences on beta-interferon, including cloning, expression, modification, and production of the protein. The candidate initially attracted interest as a broad anticancer treatment but did not deliver the expected results in that role. It was eventually approved for treating symptoms of multiple sclerosis and became associated with the name Betaseron. The company's most prominent drug-development program was recombinant interleukin-2. Several groups, including Cetus, Genentech, Immunex, and researchers in Japan, competed to clone the IL-2 gene. After Tadatsugu Taniguchi achieved the first successful cloning in 1982, Cetus produced its own recombinant IL-2 by 1983. The company collaborated with Steven Rosenberg on clinical testing. The treatment produced encouraging responses in renal-cancer patients, but its side effects were serious. In 1990, the FDA requested additional information rather than approving the product. The delay was especially damaging because Cetus had committed a large share of its available resources to producing and testing IL-2. Cetus also pursued DNA diagnostics. Partnerships with Perkin-Elmer addressed diagnostic instrumentation, while work with Kodak examined commercial diagnostic kits. During this period Kary Mullis conceived PCR, a process for amplifying selected DNA sequences. The technology later became central to research, forensic science, genetic testing, and clinical diagnostics. Mullis's 1993 Nobel Prize in Chemistry gave international recognition to research connected with Cetus and helped establish PCR as one of biotechnology's most important enabling methods. The IL-2 setback contributed to a funding crisis. Losses continued, the chief executive resigned six weeks after the FDA decision, and Cetus sold PCR patent rights to Hoffmann-La Roche. In 1991, Chiron Corporation acquired Cetus. Chiron continued the IL-2 program, which gained FDA approval in 1992 under the later name Proleukin, and it also consolidated rights associated with beta-interferon, which received clinical approval in 1993. Cetus consequently ended as an independent company, but its work continued through commercial therapeutics and the broad adoption of PCR technology. Chiron subsequently became part of Novartis.

1. 1993PCR work receives Nobel recognition

   Kary Mullis receives the Nobel Prize in Chemistry for the PCR discovery associated with his work at Cetus.

   Source
2. 1992IL-2 is approved as Proleukin

   Chiron completes development of the Cetus-originated IL-2 program, which receives FDA approval.

   Source
3. 1991Cetus merges with Chiron

   Chiron acquires Cetus, ending Cetus's period as an independent biotechnology company.

   Source
4. 1990FDA delays IL-2 approval

   The FDA requests additional information before approving the IL-2 treatment, contributing to a severe financing crisis.

   Source
5. 1983Cetus creates recombinant IL-2

   Cetus develops a proprietary recombinant IL-2 and begins clinical work with Steven Rosenberg.

   Source
6. 1982IL-2 cloning race reaches a breakthrough

   Tadatsugu Taniguchi becomes the first to clone the IL-2 gene, influencing the competitive development environment in which Cetus pursued its own recombinant version.

   Source
7. 1981Largest biotechnology IPO of its time

   Cetus raises $108 million in an initial public offering to support its expanding biotechnology programs.

   Source
8. 1971Cetus Corporation is founded

   Ronald E. Cape, Peter Farley, and Donald A. Glaser establish the company in Berkeley, California.

   Source

An early biotechnology innovator combining recombinant-drug development with molecular diagnostics and enabling DNA technologies.

• Recombinant interleukin-2Biopharmaceutical1992

  Cetus's principal therapeutic program was a recombinant form of interleukin-2, an immune-system modulator. Developed by the company in the early 1980s and tested with Steven Rosenberg, it showed activity in renal cancer but also produced significant adverse effects. FDA approval was delayed in 1990 and granted in 1992 after Chiron acquired Cetus. The treatment was subsequently marketed as Proleukin.

• Beta-interferonBiopharmaceutical1993

  Cetus developed beta-interferon with Triton Biosciences through recombinant production methods. The program was initially evaluated as a broad anticancer treatment, but its later clinical value was associated with treatment of multiple-sclerosis symptoms. After the Chiron acquisition and consolidation of related rights, the product became associated with the name Betaseron.

• Polymerase chain reaction technologyMolecular biology technology

  PCR is a DNA amplification method conceived by Kary Mullis while he was working at Cetus. It enables researchers to make many copies of selected DNA sequences and became a core technology in research, forensic analysis, genetic-disease diagnostics, and other molecular applications. Cetus later sold associated patent rights to Hoffmann-La Roche.

• 1991Chiron acquires Cetus CorporationM&A

  Cetus's expensive IL-2 development program, regulatory delay, and continuing losses weakened its position as an independent company.

  What changed. Cetus was sold to Chiron Corporation.

  Aftermath. Chiron continued the IL-2 program and assembled related beta-interferon rights. Cetus ceased operating as an independent company, while its therapeutic and PCR-related work continued through successor organizations.

  Source
• 1990Cetus sells PCR patent rights during financial pressureStrategy

  Cetus faced continuing losses and a funding crisis after the FDA requested additional information on its IL-2 application.

  What changed. The company sold patent rights connected with PCR to Hoffmann-La Roche.

  Aftermath. The transaction provided a route for PCR intellectual property to continue under Roche while Cetus remained under financial strain and was acquired by Chiron the following year.

  Source

• 1993Kary Mullis receives Nobel Prize for PCR-related work

  Kary Mullis received the Nobel Prize in Chemistry for the PCR discovery associated with research conducted at Cetus, highlighting the company's lasting scientific influence.

  Other
  Source
• 1993Beta-interferon receives clinical approval

  Rights assembled by Chiron for beta-interferon led to clinical approval after the program had originated in Cetus's collaboration with Triton Biosciences.

  RegulationProduct launch
  Source
• 1992IL-2 receives FDA approval after the Cetus acquisition

  Chiron continued Cetus's IL-2 development program, and the treatment was ultimately approved and later distributed under the name Proleukin.

  RegulationProduct launch
  Source
• 1991Chiron acquires Cetus Corporation

  Cetus was sold to Chiron Corporation, ending its independent existence and transferring responsibility for its major therapeutic programs.

  M&A
  Source
• 1990FDA requests additional information for Cetus IL-2 application

  The FDA declined to approve Cetus's IL-2 treatment at that stage and requested further information, intensifying pressure on a company already carrying heavy development costs.

  Regulation
  Source
• 1990Cetus sells PCR patent rights to Hoffmann-La Roche

  Cetus transferred patent rights related to PCR to Hoffmann-La Roche during a period of financial strain and continuing losses.

  M&AOther
  Source
• 1983Cetus develops recombinant interleukin-2 program

  The company created a proprietary recombinant form of IL-2 and began clinical work with Steven Rosenberg, establishing its principal therapeutic development program.

  Product launch
  Source
• 1981Cetus raises $108 million in biotechnology IPO

  Cetus completed an initial public offering that provided substantial funding for its expanding recombinant-drug, diagnostic, and molecular-biology programs.

  Other
  Source

1. Cetus Corporation